Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

StanChart Q1 beats forecasts on wealth management boost

(Sharecast News) - Asia-focused bank Standard Chartered reported better-than-expected first-quarter profit, driven by strong growth in its wealth management but also warned of the impact of US President Donald Trump's trade war. Pre-tax profit for the three months to March came in at $2.10bn, up from $1.91bn and the $1.905bn consensus average.

"Imposition of trade tariffs has increased global economic and geopolitical complexity, and we remain watchful of the external environment," said chief executive Bill Winters on Friday.

"Our presence in structurally high-growth markets across Asia, Africa and the Middle East is key to driving long-term sustainable value for our shareholders, and we remain focused on reinforcing these competitive advantages to drive future growth."

Net interest income rose 3% to $1.6bn while the wealth management division increased operating income by 28%.

However, credit impairment charges were up 24% year on year to $219m, mostly due to StanChart's wealth and retail banking unit, where rising rates had started to strain repayments in some unsecured portfolios.

The bank also reiterated guidance for this year and next, projecting operating income to grow at a compound annual rate of 5-7% between 2023 and 2026.

Reporting by Frank Prenesti for Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.